Skip to content

Study · Animal study (in vivo) · mouse · 2025

19 results

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.

Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W

Endocrine30 Aug 2024Cited by 11 (Europe PMC)

PMID39212900 (opens in a new tab)DOI10.1007/s12020-024-03998-8 (opens in a new tab)PepBankPUB-39212900
Publisher pagePubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide reduced body weight more effectively than liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide reduced body weight more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    DecreaseBody weight reduction versus liraglutide and tirzepatide
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Retatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide improved renal function more effectively than liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide improved kidney function more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    IncreaseRenal function improvement versus liraglutide and tirzepatide
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Retatrutide demonstrated superior effectiveness in reducing weight and improving renal function in db/db mice compared to Liraglutide and Tirzepatide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of the pro-inflammatory cytokine TNF-α.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the inflammation marker TNF-α in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal TNF-α expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of caspase-1.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the inflammation marker caspase-1 in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal caspase-1 expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of NLRP3.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the inflammation marker NLRP3 in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal NLRP3 expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of the pro-fibrotic factor fibronectin.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the scarring marker fibronectin in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal fibronectin expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of the pro-fibrotic factor α-SMA.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the scarring marker α-SMA in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal α-SMA expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide markedly suppressed kidney expression of the pro-fibrotic factor collagen I.

    In plain wordsIn mice with diabetes, retatrutide strongly lowered the scarring marker collagen I in the kidneys.

    Peptide
    Retatrutide
    Outcome
    DecreaseRenal collagen I expression
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, it markedly suppressed the expression of pro-inflammatory cytokines (TNF-α, caspase-1, and NLRP3) and pro-fibrotic factors (fibronectin, α-SMA, and collagen I) in the kidneys of mice.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide substantially enhanced liver function compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide improved liver function more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    IncreaseLiver function
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide reduced triglyceride levels compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide lowered triglycerides more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    DecreaseTriglyceride level
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide reduced cholesterol levels compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide lowered cholesterol more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    DecreaseCholesterol level
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide reduced low-density lipoprotein cholesterol compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide lowered LDL cholesterol more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    DecreaseLDL cholesterol level
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide raised high-density lipoprotein cholesterol compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide raised HDL cholesterol more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    IncreaseHDL cholesterol level
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In db/db mice, retatrutide increased the content of the intestinal metabolite butyrate compared with liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide raised gut butyrate levels more than liraglutide or tirzepatide did.

    Peptide
    Retatrutide
    Outcome
    IncreaseIntestinal butyrate content
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, Retatrutide substantially enhanced liver function, reduced triglyceride levels, cholesterol levels, low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, and increased the content of intestinal metabolite butyrate in db/db mice when compared to the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, retatrutide lowered blood glucose but did not outperform liraglutide and tirzepatide.

    In plain wordsIn mice with diabetes, retatrutide lowered blood glucose but not more than liraglutide or tirzepatide.

    Peptide
    Retatrutide
    Outcome
    DecreaseBlood glucose lowering versus liraglutide and tirzepatide
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide and tirzepatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Unfortunately, despite its ability to lower blood glucose levels, Retatrutide did not outperform the other two drugs.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, tirzepatide lowered blood glucose more than liraglutide.

    In plain wordsIn mice with diabetes, tirzepatide lowered blood sugar more than liraglutide did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBlood glucose lowering
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, Tirzepatide exhibited better effects on lowering blood glucose, weight loss, lipid reduction, and improvement of DKD compared to Liraglutide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, tirzepatide reduced body weight more than liraglutide.

    In plain wordsIn mice with diabetes, tirzepatide caused more weight loss than liraglutide did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight loss
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, Tirzepatide exhibited better effects on lowering blood glucose, weight loss, lipid reduction, and improvement of DKD compared to Liraglutide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, tirzepatide lowered lipids more than liraglutide.

    In plain wordsIn mice with diabetes, tirzepatide lowered blood fats more than liraglutide did.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLipid reduction
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, Tirzepatide exhibited better effects on lowering blood glucose, weight loss, lipid reduction, and improvement of DKD compared to Liraglutide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, tirzepatide improved diabetic kidney disease more than liraglutide.

    In plain wordsIn mice with diabetes, tirzepatide improved kidney disease more than liraglutide did.

    Peptide
    Tirzepatide
    Outcome
    IncreaseImprovement of diabetic kidney disease
    Study

    mousen: not reported in source

    db/db mice with diabetic kidney disease
    Comparator
    Liraglutide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    10 nmol/kg · intraperitoneal · 10 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, Tirzepatide exhibited better effects on lowering blood glucose, weight loss, lipid reduction, and improvement of DKD compared to Liraglutide.
    1 context sentence
    Summary · context
    Db/db mice were administered intraperitoneal injections of Liraglutide (10 nmol/kg), Tirzepatide (10 nmol/kg), and Retatrutide (10 nmol/kg) for 10 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:04 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.